Panggid Kannika, Cheewakriangkrai Chalong, Khunamornpong Surapan, Siriaunkgul Sumalee
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Obstet Gynaecol Res. 2010 Oct;36(5):1044-8. doi: 10.1111/j.1447-0756.2010.01289.x.
To evaluate the clinicopathological factors associated with recurrence of disease in non-obese women with endometrial endometrioid adenocarcinoma.
Medical records of the 138 patients who had newly diagnosed endometrial endometrioid adenocarcinoma with body mass index (BMI) <25 and underwent a complete staging surgery between 1999 and 2007 were reviewed.
The median age was 55 years (30–75 years). The median BMI was 21.3 (14.0–25.0). The International Federation of Gynecology and Obstetrics (FIGO) (1988) stages of the patients were as follows: 11 (8.0%) Ia, 30 (21.7%) Ib, 23 (16.7%) Ic, 5 (3.6%) IIa, 13 (9.4%) IIb, 12 (8.7%) IIIa, 2 (1.4%) IIIb, 38 (27.5%) IIIc, 4 (2.9%) IVb. Lymphovascular space invasion (LVSI) and lymph node metastasis was present in 73 (53%) and 38 (27.5%) patients, respectively. LVSI was significantly correlated with lymph node metastasis (P < 0.0001), advanced FIGO stage (P < 0.0001), poor histological grade (P = 0.006), and deep uterine invasion (P < 0.0001). The presence of LVSI, poor histological grade, and advanced stage were found significantly in patients who had disease recurrences (P = 0.026, P < 0.001, and P = 0.015, respectively). Patients with LVSI, when stratified by FIGO stage, had a significant lower 5-year overall survival rate (58.8% versus 76.3%, log–rank test, P = 0.04).
LVSI, poor histological grade, and advanced stage were associated with disease recurrence in non-obese women with endometrial endometrioid adenocarcinoma. Non-obese patients with LVSI-positive tumors tend to have a poorer survival rate than obese patients with LVSI-positive tumors.
评估非肥胖型子宫内膜样腺癌女性患者疾病复发的临床病理相关因素。
回顾了1999年至2007年间138例新诊断为子宫内膜样腺癌且体重指数（BMI）<25并接受了全面分期手术的患者的病历。
中位年龄为55岁（30 - 75岁）。中位BMI为21.3（14.0 - 25.0）。患者的国际妇产科联盟（FIGO）（1988年）分期如下：Ia期11例（8.0%），Ib期30例（21.7%），Ic期23例（16.7%），IIa期5例（3.6%），IIb期13例（9.4%），IIIa期12例（8.7%），IIIb期2例（1.4%），IIIc期38例（27.5%），IVb期4例（2.9%）。分别有73例（53%）和38例（27.5%）患者存在淋巴血管间隙浸润（LVSI）和淋巴结转移。LVSI与淋巴结转移（P < 0.0001）、FIGO晚期（P < 0.
